The 1-2 billion would have to come through a straight up buyout, but a premium to the sector off the P2 trials would be massive from current MC. I'd love to be a fly on the wall at HQ on interested BP chats. The reward to risks here at this price location is huge, which diminishes for me the sales exposure reductions postulated. Anything in the single digits is a great price location imo. Given the time remaining on the P2 trial, and sooner on Bioequivelancy announcement, as intimated on the investors conference, the next leg branch should pop soon. Forbearing an exogenous geo political event...
Still hoping for a dip buy opportunity here before the run. Is that wrong? Lol
News 
Market Data 
Discover 
AI
